Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jaime Steinsapir

Endocrinology, Diabetes & Metabolism Augusta, GA Medical Doctor

NPI 1396784344 CMS profile 108763

462 Furys Ferry Rd, Ste 430, Augusta, GA 30907

Open in the dashboard

General payments

$2,782

64 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$21,791 paid to institutions, not to them · program years 2019–2020

Through program year 2024, Jaime Steinsapir of Augusta, GA is reported in the CMS Open Payments database as having received $2,782 across 64 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $21,791 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 58th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $16 1
2022 General $85 6
2021 General $493 1
2020 General $155 9
2019 General $2,033 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaime Steinsapir
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Jaime Steinsapir were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Jaime Steinsapir Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $2,033 $494 $123–$2,253 $163
2020 $155 $335 $85–$1,841 $114
2021 $493 $398 $88–$1,981 $132
2022 $85 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $16 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Tosoh Bioscience, Inc. $1,078 2 payments
  2. Welch Allyn $493 1 payment
  3. Novo Nordisk Inc $204 14 payments
  4. AstraZeneca Pharmaceuticals LP $198 12 payments
  5. Tandem Diabetes Care, Inc. $119 1 payment
  6. Mannkind Corporation $107 1 payment
  7. Amgen Inc. $62 3 payments
  8. Lilly USA, LLC $53 1 payment
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $53 3 payments
  10. Sanofi Pasteur Inc. $45 2 payments
  11. Other $370 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,211 61 payments
  2. Gift $1,078 2 payments
  3. Debt forgiveness $493 1 payment
Products named General payments · program years 2019–2024
  1. 25-OH Vitamin D ST AIA-Pack $2,156 4 payments
  2. TU, AIA-PACK Calibrator Set $539 1 payment
  3. TU, ST AIA-PACK $539 1 payment
  4. None $493 1 payment
  5. FARXIGA $198 12 payments
  6. Ozempic $190 13 payments
  7. t-slim insulin pump $119 1 payment
  8. AFREZZA $107 1 payment
  9. Repatha $62 3 payments
  10. Tresiba $54 4 payments
  11. Other $812 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record